Specific active immunochemotherapy in lung cancer: a survival study
- PMID: 301428
Specific active immunochemotherapy in lung cancer: a survival study
Abstract
A radomized clinical trial of chemotherapy, immunization and immunochemotherapy among 55 patients with stages I and II carcinoma of the lung is reported. The survival rate in the immunized groups was significantly better (P = 0.001) than that in the nonimmunized groups. The results are discussed in the light of the reactivity of the patients to the specific cancer antigen.